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Abstract
There is growing evidence that genetic risk factors for common disease are caused by hereditary changes of gene
regulation acting in complex pathways. Clearly understanding the molecular genetic relationships between genetic control
of gene expression and its effect on complex diseases is essential. Here we describe the Brisbane Systems Genetics Study
(BSGS), a family-based study that will be used to elucidate the genetic factors affecting gene expression and the role of gene
regulation in mediating endophenotypes and complex diseases. BSGS comprises of a total of 962 individuals from 314
families, for which we have high-density genotype, gene expression and phenotypic data. Families consist of combinations
of both monozygotic and dizygotic twin pairs, their siblings, and, for 72 families, both parents. A significant advantage of
the inclusion of parents is improved power to disentangle environmental, additive genetic and non-additive genetic effects
of gene expression and measured phenotypes. Furthermore, it allows for the estimation of parent-of-origin effects,
something that has not previously been systematically investigated in human genetical genomics studies. Measured
phenotypes available within the BSGS include blood phenotypes and biochemical traits measured from components of the
tissue sample in which transcription levels are determined, providing an ideal test case for systems genetics approaches. We
report results from an expression quantitative trait loci (eQTL) analysis using 862 individuals from BSGS to test for
associations between expression levels of 17,926 probes and 528,509 SNP genotypes. At a study wide significance level
approximately 15,000 associations were observed between expression levels and SNP genotypes. These associations
corresponded to a total of 2,081 expression quantitative trait loci (eQTL) involving 1,503 probes. The majority of identified
eQTL (87%) were located within cis-regions.
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Introduction
Dissection of the genetic architecture underlying quantitative
traits and complex disease is essential to our understanding of the
aetiology of complex diseases that cause most of the disease burden
in society. Genome-wide association studies (GWAS) have proven
to be an effective tool for identifying common causal loci of
moderate to large effect size associated with human diseases and
traits [1], [2]. However, as has been well discussed, GWAS have
struggled to discover loci that collectively explain large proportions
of the heritability of most complex traits [3], [4]. It has been
proposed [5–7] that the nature of genetic variance for complex
disease may be different to that of Mendelian disease that are
caused by protein coding mutations, in that it may result from
hereditary changes in gene regulation rather than gene variants
that alter protein function. A number of recently published studies
support this hypothesis [8–10]. More specifically, genetic differ-
ences between individuals in quantitative traits, endophenotypes
(phenotypes that are risk factors for disease) and susceptibility to
common diseases may be caused by differences in gene expression
at a number of interacting loci [11]. Therefore, understanding the
genetic basis of gene expression is likely to lead to a better
understanding of genetic variation of quantitative traits and risk
factors for common diseases.
Transcript abundance is a proximal endophenotype affected by
genetic factors and has already facilitated the identification of
candidate susceptibility genes for metabolic disease traits [12],
psychiatric disorders [13], [14], asthma [15] and Crohn’s disease
[16]. This has mostly been possible when the tissue of expression
was relevant to the interrogated complex trait, as disease
phenotypes tend to manifest themselves only in certain tissues.
Common disease is an endpoint of a complex pathway and there
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e35430are likely to be many possible perturbations, or combinations
thereof, in the pathways that lead to disease. Understanding the
pathway as a whole, including the genetic determination of major
hubs of gene regulation and how they relate to endophenotypes,
will therefore be a major step in understanding the ultimate disease
outcome and may provide information on the optimal choice of
where to intervene in the pathway to prevent or treat disease.
Here we outline a major family-based system genetics study
initiated to enhance our knowledge about common trait
susceptibility by providing genome-wide expression and genotype
data for 962 extensively phenotyped individuals in a family based
design. This study builds on existing genotype and phenotype data
collected at Queensland Institute of Medical Research (QIMR)
through the collection of gene expression levels in whole blood
(WB) (on all individuals) and lymphoblastoid cell lines (LCL) (on a
subset of 50 MZ pairs). This study will help illuminate the genetic
parameters underlying regulation of gene expression and to
understand the genetic basis of complex traits through the
relationship between gene expression and endophenotypes. We
present a detailed description of the BSGS and report results on
the association of expression levels with SNP genotypes from 862
BSGS individuals.
BSGS resource
BSGS comprises genotypic, expression and phenotype data that
can be used to elucidate the genetic basis of gene expression and
the relationship between gene expression and complex pheno-
types. BSGS and its rationale are summarised in figure 1.
Gene expression data were generated for a total of 962
individuals from 314 families, for which we have genotype and
phenotype data. Of the 962 individuals there are 128 MZ pairs (68
female and 60 male) and 206 DZ pairs (51 female, 53 male and
102 opposite sex). For 72 families expression data were collected
on both parents as well as their offspring, allowing us to test
parent-of-origin effects for gene expression. The 314 families
comprise a variety of family structures and sizes, details of which
are given in Figure 2. Details of the pairwise relationships are
given in Table 1.
BSGS comprises the following data;
Expression. Gene expression data were collected in two
stages: Stage I - involving 50 MZ pairs, on whom expression data
were collected for both WB and LCL; Stage II - the remaining
862 individuals, where expression data were collected in WB only.
A full description of the data collection for the stage I study is given
in Powell et al. [17], and so for the sake of brevity, we focus on the
description of stage II here. Transcript expression levels in WB
were measured with over 47,000 genome-wide probes using the
Illumina HT-12 v4.0 microarray chip (see materials and methods).
Of the probes on the HT-12 v4.0 chip, approximately 29,000 are
well characterized and annotated coding transcripts, 11,000 are
coding transcript but poorly annotated, 4,000 are non-coding and
3,000 are experimentally confirmed mRNA sequences that align
to EST clusters.
Genotypic. Individuals are genotyped using the Illumina
610K chip [18–20]. After quality control procedures (see materials
and methods) over 500 k genome-wide SNPs are available.
Phenotypes. A large number of hematology and blood
biochemical phenotypes were measured at time of sample
collection and later studies [19], [20–25]. In many cases these
phenotypes have been analysed as part of a larger QIMR twin
study focusing on linkage, association and heritability analyses. A
brief summary of published results and phenotypes is given in
table 2. Of particular relevance are the phenotypes measured in
blood samples, including biochemical measures, because of their
close relationship to the tissue in which expression levels have been
measured. Such a relationship provides an ideal test case for the
systems genetics approach that we are taking.
Results
Here we present results on expression data quality and an
eQTL analysis using expression data from WB for the 862 (Stage
II) individuals in BSGS. Details of expression quality for stage I
individuals are given in Powell et al. [17].
Stage II expression data quality
Gene expression levels were generated for the 862 individuals
from WB samples using the PAXgene
TM tube system. Expression
levels of extracted mRNA were measured using Illumina
HumanHT-12 v4.0 whole genome chip. For use as a research
resource the quality of the expression data is important, although
quality control procedures are likely to differ depending on specific
analyses. Original data consists of raw, un-normalised, expression
levels with chip background levels subtracted for 47,323 probes.
Illumina software GenomeStudio also calculates a detection p-
value (see methods), which represents the probability that a given
transcript is expressed above the chip background level. A value
below a p-value threshold (i.e. 0.05) indicates a gene is detected
and thus, the number of detected transcripts is a good overall
indicator of sample expression quality, with all samples on a given
chip expected to have similar numbers of transcripts detected. All
862 samples show high numbers of probes detected with p,0.05
(mean=17,310 and SD=1,512) with similar numbers within and
between chips (Figure S1). These levels are similar or slightly
higher than other published reports using Illumina chips (for
example in Monocytes [26], Lymphoblastoid cell lines (LCL) [27],
[28], Fibroblasts and T-cells [28]).
Gene expression is known to vary between individuals due to
differences in environmental [29], [30] and genetic [31] factors.
Additionally, differences in the genetic control of gene expression
between tissues [17], [32], coupled with specific environments of
cell types, lead to certain genes being expressed in some tissues and
not others at the time of sample collection [33]. A consequence is
that we expect many probes not to be expressed in a proportion of
the individuals in our sample. Studies of gene expression data use a
Figure 1. Summary of BSGS study design. The structure of the
study design allows us to investigate fundamental questions about the
genetic basis of gene expression and their correlation with phenotypes
that are known risk factors for disease.
doi:10.1371/journal.pone.0035430.g001
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commonly used criterion is that a given gene must be detected as
expressed in a certain proportion of the samples, with the
particular proportion decided based on requirements and
constraints of the analyses. Of the 47,323 probes 5,364 (11.3%)
are not detected as expressed in any of the 862 individuals, whilst
6,281 (13.3%) are detected as expressed in all individuals (Figure
S2).
Identification of eQTL
Of the 47,323 probes whose expression levels were measured on
the chip, only probes that were well characterised and detected as
expressed in 10% of the sample were carried forward, leaving a
total of 17,926 probes (corresponding to 13,533 RefSeq genes)
whose expression was tested for association with the 528,509
SNPs. At the study wide significance threshold (5.25610
212)a
total of 14,916 associations were identified involving 10,421 SNPs
(eSNPs) and 1,503 probes. In situations where a probe had
multiple significant SNP associations, independent eQTL were
called if the distance between significant SNPs was greater than
2MB. Using this criterion a total of 2,081 eQTL were called for
the 1,503 probes with 1,357 (90%) of probes having a single eQTL
and 19 probes with greater than five eQTL. The median number
of significant SNPs within an eQTL region was 4, although 351
(16.8%) of eQTL contained over 10 significant SNPs and 27
(1.3%) over 50. Of the 10,421 eSNPs the majority (73.6%) were
associated with a single probe whilst the remaining 26.4% have
Figure 2. Samples collected in BSGS comprise of a number of different families. Family structure h represents the 50 MZ pairs comprising
the stage I study. The remaining family structures are from stage II. The numbers of each family structure are given below the pedigree diagram. By
utilising expression information contained between and within twin pairs, siblings and between progeny and parents we are able to estimate genetic
and non-genetic variance components using linear mixed models.
doi:10.1371/journal.pone.0035430.g002
Table 1. Relationship pairing between 962 individuals in BSGS.
Relationship pairs Code N Notes
Monozygotic twins MZ 128 68 female pairs; 60 male pairs; 50 MZ pairs form stage I, where we have expression
data from both WB and LCL RNA sources
Dizygotic twins DZ 206 51 female pairs; 53 male pairs; 102 mixed sex pairs
Siblings SIB 343 81 female pairs; 82 male pairs; 180 mixed sex pairs
Parent – Offspring PO 425 98 father – daughter pairs; 103 father – son pairs; 113 mother – daughter pairs; 111
mother – son pairs
Parent – Parent PP 71
doi:10.1371/journal.pone.0035430.t001
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maximum being eight.
Among the 2,081 eQTL the SNP with the smallest p-value had
R
2 (proportion of expression variability explained) from 4.6% to
.80% with a median of 12.1% (Figure 3). A total of 328 eQTLs
had R
2 greater than 25% and 61 greater than 50%. It is worth
noting that these estimates will be biased upwards because
hypothesis testing and estimation were performed on the same
data (‘‘winner’s curse’’).
Of the 2,081 eQTL, 1,810 (87%) are cis-acting, being located
within a 2MB region either side of the 39 or 59 end of the
Transcription Start Site (TSS). The remaining 271 eQTL are trans-
acting, although the majority of these (232) are located on the same
chromosome as their probes TSS. Twelve probes had both cis-and
trans-acting eQTL. To explore the location of cis-eQTLs, the
distance of the most significant SNP for each cis-eQTL per probe
was mapped relative to the TSS. In agreement with previous studies
[28], [34–35] a strong signal was found close to the TSS, with no
discernable trend in a 39 or 59 direction (Figure 4). This symmetrical
trend is likely to reflect variation in core regulatory sequences such
as promoter elements. Details of the top twelve cis-eQTL (based on
eSNP p-values) are given in table 3.
Regulatory control for gene expression, particularly trans-acting,
is not evenly distributed across the genome [36]. To provide an
outline of the positions of regulatory control for gene expression
across the genome, we produced a Manhattan plot showing the
number of eSNP (each eSNP represents a single eQTL) within
each 1MB region (Figure 5). Cis-acting eSNPs are distributed
across the genome, as has been reported by multiple studies [26–
27], [37]. We observe that trans-acting eSNPs are often found in
close proximity to one another, supporting the concept of trans-
regulatory hotspots [38].
Many studies mapping eQTL consider just associations within
the cis-region: the main benefit being a considerably reduced
burden of multiple testing compared to studies including trans-
acting SNPs. Given correlations exist between both SNP
genotypes and probe expression levels, it is likely that our study-
wide significance threshold (corrected for all SNP by probe tests)
results in true associations being missed. By reducing the
significance threshold to less conservative levels, the number of
trans-eQTL considerably increased, as expected by chance
(Table 4). However, the number of cis-eQTL only moderately
increased, indicating that conservative threshold used did not
result in a considerable under estimation of the true number of cis-
eQTL (Table 4).
Discussion
Through understanding the genetic control of gene expression
and its relationship with indicators of common disease we can gain
a better understanding of disease itself. Common disease is an
endpoint of a complex pathway of genetic and environmental
factors and there are likely to be many possible perturbations in
the pathways that lead to disease. Gaining insights into the
pathway as a whole, including the genetic control of major hubs of
gene regulation and how they relate to endophenotypes, is a major
step in understanding the ultimate outcome of (disease) and may
provide information on the optimum choice of where to intervene
in the pathway to prevent or treat disease. Recent success at
identifying genetic determinants for networks of regulatory control
affecting metabolic disease [39] has highlighted the application of
systems genetic approaches in understanding the aetiology of
complex phenotypes. We aim to use BSGS for the identification of
polymorphisms, or combinations thereof, that affect gene
regulation in one or more genes which in turn cause differences
between individuals in endophenotypes or susceptibility to disease
and may lead to drug discovery or other treatments to decrease the
burden of common disease in society.
The cellular origin of many biochemical and blood phenotypes
is often complex with some traits originating in other tissues but
displayed in blood. For example, insulin originates from b-cells in
the pancreas but is carried in the blood where is performs its role
of regulating glucose levels. However, insulin levels are regulated
Table 2. Central phenotypes in BSGS and a brief summary of previous studies identifying genetic parameters and association
signals.
Phenotypes Summary Reference
Hemoglobin concentration Hemoglobin phenotypes have been associated with SNPs in
TMPRSS6, LRRC16A, HK1 and HK2.
[19], [20]
Red blood cell count Association with SNPs close to IRX6. [20]
Platelet count Platelet count has suggestive association with SNPs in KCNIP. [20]
White blood cell count White blood cell count has suggestive association with SNPs
in MACF1.
[20]
Monocytes Monocyte count is associated with SNPs close to BAG4 and ITGA4. [20]
Eosinophils Eosinophil count has suggestive association with SNPs in ITPR1. [20]
CD4+/CD8+ T-cell ratio Collectively, these phenotypes are associated with SNPs in the MHC
and the Schlafen family of genes. They are also endophenotypes for Type 1
Diabetes, HIV-1 immune control and autoimmune diseases.
[25]
Plasma Cholesterol (HDL and LDL) and Triglyceride
concentrations
A known endophenotypes for cardiovascular disease. Data comprising part
of BSGS have shown strong associations between Cholesterol and genes on
chromosome 19 and between Triglyceride and genes on chromosome 7.
[18], [22]
Blood pressure An important endophenotype for hypertension. Data comprising part of
BSGS have shown strong associations between blood pressure and genes
on chromosomes 4,5,14 and 17.
[23], [24]
Iron, Ferritin and Transferrin levels Collectively, these phenotypes show association with SNPs in TMPRSS6,
HFE, PGM1 and TF.
[19], [61],
[62]
doi:10.1371/journal.pone.0035430.t002
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2 observed for the best eSNP from the 1,885 eQTLs.
doi:10.1371/journal.pone.0035430.g003
Figure 4. The distribution of cis-eSNPs distance from the Transcription Start Site (TSS). The distances of eSNPs from the TSS were divided
into 50KB bins across the cis-region.
doi:10.1371/journal.pone.0035430.g004
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reasonable to expect that the expression of some genes in blood
will have an effect on insulin levels. Thus, using a tissue closely
related to phenotypes we are able to relate transcript abundance to
the blood and biochemical traits and hopefully expound the role of
gene regulation in mediating endophenotypes and complex
disease. Nevertheless, findings should be analysed with caution
as we and others [17], [32], have recently shown that the genetic
basis for gene expression is often different between tissues.
We hypothesise that the indirect route from genotype to
phenotype via gene expression is more informative to elucidate the
nature of complex trait variation than the direct route from
genotype to phenotype. The expression data collected from
families allows us to estimate quantitative genetic variance
components through the use of linear mixed models and
estimation methods such as restricted maximum likelihood
(REML) [40]. By utilising information contained between and
within twin pairs, siblings and between progeny and parents we
are able to estimate additive and non-additive genetic effects of
gene expression and can explicitly test a variance partition model
that includes parent-of-origin effects.
Here we have presented results of an eQTL study involving
,18 k probes, each tested against .500 k SNPs. Despite
numerous large scale studies reporting eQTL [26–28], [34],
[37], [41–42], generating eQTL results for a particular study is
important as differences in the genetic control of gene expression
between populations [43–45] and between tissues [17], [32] is well
known. Furthermore, here, and elsewhere [26], [41–42] large
sample sizes have permitted the investigation of trans-acting eSNP
often ignored by smaller studies [28], [34].
Table 3. Top cis-eQTL results.
Probe ID Gene Probe Chromosome TSS bp Top SNP Top SNP location -log10 p-value R
2
ILMN_1715169 HLA-DRB1 6 32654825 rs9271170 6 - 32577889 131.5 73.5
ILMN_1743145 ERAP2 5 96274820 rs10051637 5 - 96279490 131.0 81.6
ILMN_1798177 CHURC1 14 64471249 rs7143432 14 - 65379146 130.4 83.0
ILMN_2209027 RPS26 12 54722494 rs10876864 12 - 56401085 122.0 74.6
ILMN_2403228 CLEC12A 12 10029119 rs7313235 12 - 10132283 121.3 75.8
ILMN_2352023 RIPK5 1 203378372 rs12139373 1 - 205054879 114.4 70.2
ILMN_2312606 IRF5 7 127973722 rs6965542 7 - 128655918 112.6 74.8
ILMN_1791511 TMEM176A 7 150133038 rs7806458 7 - 150476888 107.5 66.4
ILMN_2038775 TUBB2A 6 3154070 Rs9392465 6 - 3162378 107.2 66.7
ILMN_3298167 ZSWIM7 17 15879944 rs1045599 17 - 15879910 105.5 65.9
ILMN_1661266 HLA-DQB1 6 32736001 rs9273349 6 - 32625869 102.0 61.2
ILMN_2313901 PAM 5 102340879 rs28092 5 - 102149795 99.7 66.2
The chromosome and base pair position of the probe transcription start site (TSS) are given for each probe. R
2 is the proportion of transcript level variance explained by
the SNP with the strongest association.
doi:10.1371/journal.pone.0035430.t003
Figure 5. Positions of cis (A) and trans (defined as greater than 2MB from the transcription start site) (B) eSNP across the genome.
The number of eSNP within 1MB bins is shown. A single eSNP represents a unique eQTL.
doi:10.1371/journal.pone.0035430.g005
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Sample Collection
Individuals present in this study were recruited as part of the
Brisbane Twin Nevus and cognition studies (known as BTN and
MAPS respectively). This study was approved by the Queensland
Institute for Medical Research-Human Research Ethics Commit-
tee. All participants gave informed written consent. As described in
detail elsewhere [21], [46–50], adolescent MZ and DZ twins, their
siblings, and their parents have been recruited over a 16 year
period into an ongoing study of the genetic and environmental
factors influencing pigmented nevi and the associated risk of
developing skin cancer and cognition. The sample is of northern
European origin (mainly Anglo-Celtic). A Principal Component
Analysis (PCA) comparing individuals in this study to HapMap3
[51] and GenomEUtwin [52] populations shows the close
similarity of ancestry to northern European populations (Figure
S3). All participants gave informed consent, and the study protocol
was approved by the appropriate institutional review boards.
Analysis of Stage II data
Genotyping. DNA samples from each individual were
genotyped by the Scientific Services Division at deCODE
Genetics, Iceland, using the Illumina 610-Quad Beadchip.
Genotypes were called with the Illumina BeadStudio software.
Full details of genotyping procedures are given in Medland et al.
[53]. Standard QC filters were applied so that further analysis was
on samples and SNPs with high data quality. We first applied
filters to SNP data before evaluating genotyping quality per
individual. After removing SNPs with minor allele frequencies
(MAF) ,1% with a mean BeadStudio GenCall ,0.7 a total of
528,509 remained for further analysis.
Gene expression quantification. Whole blood for
expression profiling was collected directly into PAXgene
TM tube
(QIAGEN, Valencia, CA). Total RNA was extracted from
PAXgene
TM tubes using the WB gene RNA purification kit
(QIAGEN, Valencia, CA). RNA from all samples was run on an
Agilent Bioanalyzer to assess quality and to estimate RNA
concentrations RNA was converted to cDNA, amplified and
purified using the Ambion Illumina TotalPrep RNA Amplification
Kit (Ambion).
Expression profiles were generated by hybridising 750 ng of
cRNA to Illumina HumanHT-12 v4.0 Beadchip according to
Illumina whole-genome gene expression direct hybridization assay
guide (Illumina Inc, San Diego, USA). Briefly, 500 ng of total
RNA were used to generate biotinylated cRNA, which was
fragmented and hybridised to an Illumina whole genome
expression chip, HumanHT-12 v4.0 for 18 h at 58uC. Beadchips
were then washed and stained and subsequently scanned to obtain
fluorescence intensities. Samples were scanned using an Illumina
Bead Array Reader. Samples were randomised across chips and
chip positions, with check for balance across families, sex and
generation.
eQTL analysis
Normalisation and processing. The following
normalisation procedures were applied to the raw expression
data for the eQTL analysis. Pre-processing of data generated by
the Illumina Bead Array Reader was done using Illumina
software, GenomeStudio (Illumina Inc., San Diego). Pre-
processing included; correction for chip background effects,
removal of outlier beads, computation of average bead signal
and calculation of detection p-values using negative controls
present on the array. Removal of chip background effects can lead
to negative expression levels for transcripts with low levels of
measured expression. To avoid problems with further
normalisation procedures, negative values were changed to
missing data identifiers. Thus, in subsequent normalisation
procedures and analyses probes coded as missing are ignored.
The Illumina HT-12 v4.0 chip contains 47,323 probes,
although some probes are not assigned to RefSeq genes. To avoid
spurious associations, we removed 678 probes for which at least
one HapMap 3 (NCBI build 36, dbSNP b126) SNP was within the
probe sequence [54]. For the eQTL analysis we removed any
probes where less than 10% of samples had a detection p-
value,0.05. Of the 24,317 probes retained, the mean of the
proportion of samples with p-values,0.05 was 97%, implying that
relatively little missing data remained within the expression
dataset. After removing 6,322 putative and/or not well-charac-
terised genes i.e. probe names starting with HS (n=1,841), KIAA
(n=158) and LOC (n=4,323), 17,926 well-characterised detected
probes remained for analysis, which corresponds to 13,486 RefSeq
genes.
To minimise the influence of overall signal levels, which may
reflect RNA quantity and quality rather than a true biological
difference between individuals, the following standardisation
procedures were applied to the 17,926 probes. Adjusted expression
levels for each probe were transformed using a quantile
transformation [55], [56] to achieve a stabilized distribution
across average expression levels. Further normalisation was
performed to allow expression levels to be compared across chips
and genes. This was achieved fitting a linear mixed model;
Table 4. Number of associations and eQTL at various levels of significance threshold.
Significance
threshold Total associations
Expected number
of associations
Total significant
SNPs
Probes with 1+
significant SNP eQTL Cis-eQTL Trans-eQTL
10e
28 31,032 951 20,068 3,969 5,679 2,673 3,006
10e
210 20,049 9.5 13,319 1,933 2,512 1,953 559
5.25e
212 14,210 0.05 10,160 1,503 1,885 1,529 256
10e
215 10,519 0 7,468 1,126 1,507 1,256 251
10e
225 4,362 0 3,382 572 731 639 92
10e
250 896 0 764 185 199 172 27
.10e
2100 6 0 0 5 5 2 7 2 72 25
The study-wide significance threshold employed for our eQTL analysis is highlighted. The expected number of associations is the number of association that are
expected to be observed under the null hypothesis of no associations between probe expression levels and SNPs.
doi:10.1371/journal.pone.0035430.t004
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Where yijk is the log-transformed expression level for individual i
on chip j. The variable m represents the mean expression level
across all individuals and Cj and Pk are random effects removing
variation in the data due to chip j and chip position k respectively,
and eijk is the residual. The between chip variance is expected to
be small due to the scaling that was performed during the pre-
processing of the data. The residuals from this model were used in
all further analyses. To increase robustness, the distribution of
normalised expression levels for each probes were tested for
deviation from normality using the Shapiro-Wilk test. All 17,926
probes had normally distributed (p,0.05) expression levels.
Testing for association. We tested for association between
the 528,509 genotyped SNPs and the normalised expression levels
of the 17,926 probes using the FASTASSOC component of
MERLIN [57], [58]. The FASTASSOC option fits a simple linear
regression model to estimate an additive effect for each probe and
SNP combination, with SNP genotypes coded as the number of
copies of the minor allele (0, 1 or 2) carried by each individual. We
used the Lander-Green algorithm [58], [59], implemented in
Merlin, to estimate expected genotype scores for individuals with
missing genotype data. Covariates of sex and generation were
included in the model, where generation denotes either the
parental or the adolescent generation. Previous analysis has shown
(not published) that generation is a useful substitute for age without
the burden of additional degrees of freedom. The model applies a
variance component approach to account for the correlations
between different expression levels within each family. The model
fit is evaluated using a score test, which substantially reduces
computational time compared to maximum-likelihood methods, at
the expense of a slight loss of power [58].
Conditional regression analysis was used to address the potential
to miss secondary eQTL in linkage disequilibrium (LD) with other
eQTL. For each probe with an identified eQTL we corrected for
the main effects of the top eSNP (SNP with the largest R
2)b y
regressing its genotypes against the expression levels. Residuals
from this analysis were then used for second round of eQTL
mapping, allowing us to detect independent eQTL. If additional
eQTL were identified from this second round of analysis, the
process was repeated, correcting for the main effects of the top
eSNP from the first and second eQTL using multivariate
regression.
Associations were evaluated in two categories depending on the
location of the SNP relative to the transcription start site (TSS).
Cis-eQTL were defined as associations between SNPs within 2MB
of either the 39 or 59 end of the TSS. We defined trans-associations
as associations involving SNPs elsewhere in the genome. To
correct for multiple testing, we used a study-wide significance level
of 0.05, corrected for the number of SNP by probe associations
tested, corresponding to a p-value threshold of 5.25610
212.
We tested for the effects of population structure and cryptic
relatedness between individuals by applying the method ‘genomic
control’ [60] to results of the association analysis. We derived a
coefficient of 1.002, indicating negligible population stratification.
Supporting Information
Figure S1 GenomeStudio provides a p-value for each
transcript in each sample. For a given sample the number of
transcripts with p-values below a given threshold provides an
indication of its quality. Figure S1 shows the number of transcripts
with p,0.05 for each sample with each colour representing a
single chip.
(DOCX)
Figure S2 The distribution of the number of probes
detected as expressed in stage II. A total of 47,323 are
measured on the Illumina HT-12 v4.0 chip, of these 5,364 (11.3%)
are not detected as expressed in any of the individuals, whilst 6,281
(13.3%) are detected as expressed in all individuals.
(DOCX)
Figure S3 A Principle Component Analysis (PCA) of 16
global populations and the individuals collected in this
study. Principal Component one (PC1) and two (PC2) values
were derived from approximately 280,000 autosomal markers.
Populations samples marked with *1 were collected as part of the
HapHap3 project [1] and *2 as part of the GenomEUtwin project
[2]. ASW
*1 African Americans, CEU
*1 European Americans,
CHB
*1 Han Chinese, CHD
*1 Chinese, GIH
*1 Guajarati-Indians,
JPT
*1 Japanese, LWK
*1 Luhya Kenyans, MEX
*1 Mexicans,
MKK
*1 Maasai Kenyans, TSI
*1 Italians, TRI
*1 Yorubans
Nigeria, DEN
*2 Danish, FIN
*2 Finish, NET
*2 Dutch, SWE
*2
Swedish, UK
*2 British.
(DOCX)
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